Novartis anti-inflammatory drug candidate enters clinical evaluation for cardiovascular outcomes

Novartis has acquired a drug candidate that demonstrated a reduction in inflammatory markers, shifting focus to whether this mechanism translates into improved cardiovascular health outcomes. It remains uncertain if the drug's efficacy in reducing inflammation will correlate with a statistically significant decrease in heart-related morbidity or mortality in upcoming trials.